Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia
NCT00234481 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL
Last updated 2008-06-04
Summary
The purpose of this study is to assess the safety and tolerability of different doses of XL844 when given orally to adults with recurrent or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Conditions
Interventions
- DRUG
-
XL844
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT04315324 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
NCT03571321 ·Status: RECRUITING ·Phase: PHASE1
-
Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
NCT02200848 ·Status: TERMINATED ·Phase: PHASE1
-
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
NCT00098488 ·Status: TERMINATED ·Phase: PHASE1
-
Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLL
NCT00344786 ·Status: TERMINATED ·Phase: PHASE1
-
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
NCT00485966 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase l/II Study of Ruxolitinib for Acute Leukemia
NCT01251965 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of MDX-1342 in Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00593944 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Dose-escalation Study to Evaluate the Safety and Pharmacokinetics (PK) of Palifermin in Subjects With Acute Leukemias Undergoing HSCT
NCT00460421 ·Status: COMPLETED ·Phase: PHASE1
-
Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT00439231 ·Status: COMPLETED ·Phase: PHASE2
-
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
NCT00346632 ·Status: TERMINATED ·Phase: PHASE1
-
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01246622 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
NCT04775745 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase I/II Trial of Idiotypic Vaccination for Chronic Lymphocytic Leukemia Using a Genetic Approach
NCT00038415 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)
NCT04225676 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL)
NCT00046488 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
NCT06708897 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
NCT02435849 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
NCT04771572 ·Status: RECRUITING ·Phase: PHASE1
-
Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
NCT04504708 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
NCT03624036 ·Status: TERMINATED ·Phase: PHASE1
-
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Troxacitabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00012259 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia
NCT01271283 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT03384654 ·Status: COMPLETED ·Phase: PHASE2